Opinion|Videos|January 17, 2025
Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Designing Effective Value-Based Oncology Models: Lalan Wilfong, MD
4
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
5